GlassScriptPhysician profile
Nancy Shrestha
NPI 1003230517
$2,699.74
in general payments reported to CMS, 2019-2025
28 companies · $808 in 2025
The $808 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.48 · 2020: $19.12 · 2021: $121 · 2022: $185 · 2023: $330 · 2024: $1,223 · 2025: $808.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,361.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,361.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $267.82 | 2023-2025 | Jardiance, Mounjaro, Zepbound |
| Novo Nordisk INC | $192.15 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $169.97 | 2024-2025 | Freestyle Libre 3 |
| Xeris Pharmaceuticals, INC. | $168.80 | 2024-2025 | Recorlev |
| Dexcom, INC. | $157.56 | 2023-2024 | Dexcom G6 Transmitter |
| Medtronic, INC. | $154.10 | 2024 | Minimed 780g |
| Sequel Med Tech, LLC | $149.99 | 2025 | Twiist |
| Tandem Diabetes Care, INC. | $145.79 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Amgen INC. | $139.03 | 2024-2025 | Evenity, Prolia |
| Recordati_rare_diseases_inc. | $137.36 | 2024-2025 | Isturisa, Signifor Lar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $121.40 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $98.90 | 2022 | |
| Sanofi-Aventis U.S. LLC | $94.25 | 2024 | |
| Horizon Therapeutics Plc | $86.57 | 2022 | |
| Insulet Corporation | $83.91 | 2024 | Omnipod |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beta Bionics, INC. | $80.01 | 2024 | Ilet Bionic Pancreas |
| Amneal Pharmaceuticals LLC | $71.36 | 2023-2025 | Unithroid |
| Antares Pharma, INC. | $67.58 | 2024-2025 | Xyosted |
| Radius Health, INC. | $61.74 | 2023-2025 | Tymlos |
| Halozyme INC | $46.13 | 2023 | |
| Tolmar, INC. | $45.20 | 2024 | |
| Ibsa Pharma INC. | $34.42 | 2023-2024 | Tirosint, Tirosint, Licart |
| Abbvie INC. | $34.14 | 2024 | |
| Ascendis Pharma Endocrinology INC | $29.32 | 2025 | Yorvipath |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.12 | 2020 | |
| Mannkind Corporation | $16.29 | 2024 | |
| Novartis Pharmaceuticals Corporation | $14.35 | 2024 | |
| Astellas Pharma US INC | $12.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Shrestha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.